Showing results (151-160 of 226) with videos related to

Sort By:
Pageof 23
Atherosclerosis Plus|March 15, 2024
The effect of hydroxychloroquine on cholesterol synthesis depends on the profile of cholesterol metabolism. A controlled clinical studyPiia Simonen, Lotta Ulander, Kari K Eklund, et al.
Clinical Pharmacology and Therapeutics|April 5, 2008
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivoA Tornio, M Niemi, M Neuvonen, et al.
Journal of Clinical Pharmacology|May 6, 2011
Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporinStefanie Hennig, Joakim Nyberg, Samuel Fanta, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 29, 2024
Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitorsHelinä Kahma, Marie-Noëlle Paludetto, Mikko Neuvonen, et al.
Clinical Pharmacology and Therapeutics|May 9, 2000
Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylationJ T Backman, J Mäenpää, D J Belle, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 24, 2009
CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probeJanne T Backman, Johanna Honkalammi, Mikko Neuvonen, et al.
Clinical Pharmacology and Therapeutics|June 20, 2020
Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19Taavi J K Kaartinen, Aleksi Tornio, Tuija Tapaninen, et al.
Basic & Clinical Pharmacology & Toxicology|January 26, 2006
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitroMarika T Granfors, Jun-Sheng Wang, Lauri I Kajosaari, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 28, 2014
Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye dropsJukka Mäenpää, Marjo Volotinen-Maja, Hannu Kautiainen, et al.
Basic & Clinical Pharmacology & Toxicology|September 11, 2014
Intravenous lipid emulsion given to volunteers does not affect symptoms of lidocaine brain toxicityJuho A Heinonen, Erik Litonius, Tapani Salmi, et al.
Pageof 23